sábado, 7 de septiembre de 2019

Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update

Contents:

Amikacin Liposome Therapy Has Similar Efficacy as Tobramycin for P. aeruginosa, Study Shows

Sep 06, 2019 07:30 am | Steve Bryson PhD



AmikacinAmikacin liposome inhalation suspension (ALIS) showed the same efficacy and similar safety profile as tobramycin inhalation solution (TIS) for the treatment of cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infection, a comparative clinical study showed. The study, “Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis,” was published in the Journal of Cystic Fibrosis. CF patients often […]
The post Amikacin Liposome Therapy Has Similar Efficacy as Tobramycin for P. aeruginosa, Study Shows appeared first on Cystic Fibrosis News Today.
Read More
share on TwitterLike Amikacin Liposome Therapy Has Similar Efficacy as Tobramycin for P. aeruginosa, Study Shows on Facebook

Claire’s Place Foundation Glow Ride Will Include Virtual Riders This Year

Sep 05, 2019 07:00 am | Marisa Wexler MS



Glow RideClaire’s Place Foundation is preparing for its 5th Annual Glow Ride event to raise money to support families affected by cystic fibrosis. The 3.4 mile-long bike ride will take place Saturday at 5:30 p.m. at the piers of Hermosa Beach and Manhattan Beach in California. In addition to in-person riders, for the first time this year […]
The post Claire’s Place Foundation Glow Ride Will Include Virtual Riders This Year appeared first on Cystic Fibrosis News Today.
Read More
share on TwitterLike Claire’s Place Foundation Glow Ride Will Include Virtual Riders This Year on Facebook

Recent News

Blocking Specific Protein Complex May Treat Chronic P. aeruginosa Infections in CF, Study Suggests
I’m Learning to Celebrate the Imperfect Milestones
The Kind of Friend We Deserve
‘Disorder’ Film Festival Offers Look at Siblings Touched by Rare Diseases
More CFRD Screening Can Improve Outcome of People with CF, Study Suggests

No hay comentarios:

Publicar un comentario